Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

被引：0

作者：

Richardson, Paul ^{[1
]}

Sandhu, Irwindeep ^{[2
]}

Oriol, Albert ^{[3
,4
]}

Raab, Marc S. ^{[5
]}

White, Darrell ^{[6
,7
]}

LeBlanc, Richard ^{[8
]}

Perrot, Aurore ^{[9
]}

Ocio, Enrique ^{[10
]}

Raje, Noopur ^{[11
]}

Hansen, Charlotte Toftmann ^{[12
]}

Zhou, Zehua ^{[13
]}

Civardi, Tiziana ^{[14
]}

Ghiddi, Alessandro ^{[14
]}

Katz, Jessica ^{[13
]}

Peluso, Teresa ^{[14
]}

Dimopoulos, Meletios A. ^{[15
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Alberta, Edmonton, AB, Canada

[3] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[4] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain

[5] Univ Klinikum Heidelberg, Heidelberg, Germany

[6] Dalhousie Univ, Halifax, NS, Canada

[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[8] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[10] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain

[11] Massachusetts Gen Canc Ctr, Boston, MA USA

[12] Odense Univ Hosp, Odense, Denmark

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Celgene Int Sarl, Boudry, Switzerland

[15] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-053

引用

页码：S33 / S33

页数：1

共 50 条

[41] PHASE I TRIAL OF VORINOSTAT PLUS BORTEZOMIB (BORT) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS)
Badros, Z.
Philip, S.
Niesvizky, R.
Goloubeva, O.
Harris, C.
Zweibel, J.
Wright, J.
Burger, A.
Baer, M.
Egorin, M.
Grant, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 258 - 258
[42] CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma
Wong, Lilly
Narla, Rama Krishna
Leisten, Jim
Bauer, Daniel
Groza, Matthew
Gaffney, Bonny
Havens, Courtney G.
Choi, Justin
Houston, Jack
Lopez-Girona, Antonia
Hansen, Joshua
Cathers, Brian E.
Carmichael, James
Pierce, Daniel W.
BLOOD, 2019, 134
[43] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
Lentzsch, Suzanne
Quach, Hang
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Thiyagarajah, Piruntha
Amin, Himal
Casneuf, Tineke
Sonneveld, Pieter
Schecter, Jordan
Hungria, Vania T. M.
BLOOD, 2017, 130
[44] A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Chari, A.
Htut, M.
Zonder, J.
Fay, J.
Jakubowiak, A.
Harrison, B.
Lau, K.
Burt, S.
Hilder, B.
Ptaszynski, A. M.
Rush, S.
Kaufman, J.
HAEMATOLOGICA, 2014, 99 : 113 - 113
[45] A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
Richardson, Paul G.
Amatangelo, Michael
Berenson, James R.
Cerchione, Claudio
Dimopoulos, Meletios A.
Hansen, Charlotte Toftmann
Hwang, Soo Jeong
Koo, Phillip
Kuroda, Junya
Oriol, Albert
Orlowski, Robert Z.
Quach, Hang
Raab, Marc S.
Rocci, Alberto
Wang, Yue
White, Darrell
Yu, Brian
Zhou, Zehua
Katz, Jessica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
Jakubowiak, Andrzej J.
White, Darrell
Moreau, Philippe
Facon, Thierry
Vij, Ravi
Kroog, Glenn Scott
Kopit, Justin
Singhal, Anil
Palumbo, Antonio Pierangelo
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[47] Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)
Badros, A. Z.
Philip, S.
Niesvizk, R.
Goloubeva, O.
Harris, C.
Zweibel, J.
Wright, J. J.
Burger, A.
Baer, M. R.
Egorin, M. J.
Grant, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[48] A Phase 1 study Of CC-92480, a novel CELMoD agent, in patients with relapsed/refractory multiple myeloma: pharmacodynamic effects of dose and schedule
Wong, Lilly
Lamba, Manisha
Jimenez Nunez, Maria Dolores
Bauer, Daniel
Bahlis, Nizar J.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Pourdehnad, Michael
Pierce, Daniel W.
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 152 - 153
[49] First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
van de Donk, Niels W. C. J.
Popat, Rakesh
Zonder, Jeffrey A.
Minnema, Monique C.
Larsen, Jeremy
Tuong Vi Nguyen
Chen, Min S.
Bensmaine, Amine
Cota, Mariana
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[50] Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Hansen, Joshua D.
Correa, Matthew
Nagy, Mark A.
Alexander, Matt
Plantevin, Veronique
Grant, Virginia
Whitefield, Brandon
Huang, Dehua
Kercher, Timothy
Harris, Roy
Narla, Rama Krishna
Leisten, Jim
Tang, Yang
Moghaddam, Mehran
Ebinger, Katalin
Piccotti, Joseph
Havens, Courtney G.
Cathers, Brian
Carmichael, James
Daniel, Thomas
Vessey, Rupert
Hamann, Lawrence G.
Leftheris, Katerina
Mendy, Derek
Baculi, Frans
LeBrun, Laurie A.
Khambatta, Gody
Lopez-Girona, Antonia
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 6648 - 6676

← 1 2 3 4 5 →